CIK 0000072444
- Accelerated filer
- Smaller reporting company
Vaxart, Inc.
Sign in to watch- Ticker
- VXRT
- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 591212264
- Phone
- +1 650-550-3500
- Business address
- 310 UTAH AVENUE, SUITE 150, SOUTH SAN FRANCISCO, CA
- Former names
- Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., NABI BIOPHARMACEUTICALS, NABI BIOPHARMACEUTICALS, NABI /DE/, NORTH AMERICAN BIOLOGICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2013-05-01 | COX GEOFFREY F Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2013-05-01 | Cook Peter Chapman Director | Grant or award · Stock Option (Right to Buy) | +15,000 | 15,000 | ||
| 2013-05-01 | VANLENT ANNE Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2013-05-01 | DOUGHERTY MICHAEL R Director | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2012-11-12 | PLUMB RUSSELL H CEO & President | Grant or award | +143,322 | 143,322 | ||
| 2012-11-12 | PLUMB RUSSELL H CEO & President | Grant or award · Stock Option (Right to Buy) | +573,286 | 573,286 | ||
| 2012-11-12 | PATTI JOSEPH M EVP, Corporate Dev & Strategy | Grant or award | +71,661 | 71,661 | ||
| 2012-11-12 | PATTI JOSEPH M EVP, Corporate Dev & Strategy | Grant or award · Stock Option (Right to Buy) | +358,304 | 358,304 | ||
| 2012-04-05 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Sale | −5,167 | $1.90 | $10K | 105,128 |
| 2011-05-25 | DAVIS PETER B Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2011-05-25 | CASTALDI DAVID L Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2011-05-25 | LYNCH TIMOTHY P Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2011-05-25 | HARVEY RICHARD A JR Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2011-05-25 | COX GEOFFREY F Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2011-05-25 | Aryeh Jason Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2011-05-16 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Sale | −7,500 | $5.53 | $41K | 115,171 |
| 2011-05-16 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Sale | −4,876 | $5.48 | $27K | 110,295 |
| 2011-04-05 | FAHIM RAAFAT E F President, CEO and CFO | Sale | −13,283 | $5.76 | $76K | 373,473.94 |
| 2011-04-05 | Kessler Paul D. SVP Clinical, Med. & Reg.; CMO | Sale | −8,596 | $5.76 | $49K | 122,671 |
| 2011-04-01 | FAHIM RAAFAT E F President, CEO and CFO | Grant or award | +50,000 | 386,756.94 |
Page 26 of 42 · 830 trades